FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385952914> ?p ?o ?g. }

• W4385952914 abstract "The present study aimed to study the efficacy and adverse effects of anti‑B‑cell maturation antigen (BCMA) chimeric antigen receptor T (CAR‑T) cell therapy in relapsed or refractory multiple myeloma. Patients were divided into three dose groups based on cell therapy concentration. After CAR‑T cell therapy for 10 patients with recurrent or refractory multiple myeloma, the patients were monitored and evaluated regularly to observe the efficacy and adverse reactions of CAR‑T cell therapy. At a median follow‑up of 337 (253‑504) days, one patient succumbed 24 days due to rapidly progressing disease. The overall response rate of nine patients was 88.9%, including 77.8% (7/9) with minimal residual disease negative complete remission (CR) and 11.1% (1/9) with partial remission. A total of three patients were maintained in remission state for more than a year and eight were maintained for more than six months. Among the three patients with extramedullary invasion, two extramedullary lesions disappeared and one was stable. The highest copy number of CAR‑T cells in seven patients with CR was >1x105 copies/µl gDNA, and the best therapeutic effect can be achieved within 30 (7‑30) days after the copy number of CAR‑T cells reached 1x105 copies/µl genomic DNA. The median onset time in the nine patients was 43 (22‑169) days, and the median progression‑free survival was 337 (253‑504). Among the 10 patients, nine (90%) had cytokine release syndrome, all of which were below grade II. There were nine (90%) patients with hematological adverse reactions, six (60%) patients with severe anemia, five (50%) patients with grade III and above leukopenia, five (50%) patients with granulocytopenia, four (40%) patients with grade III and above thrombocytopenia, and three (30%) patients with grade III and above pancytopenia. It was concluded that anti‑BCMA CAR‑T cell therapy is a promising treatment method for relapsed or refractory multiple myeloma and extramedullary invasion, with stable efficacy and controllable adverse effects." @default.
• W4385952914 created "2023-08-18" @default.
• W4385952914 creator A5002802795 @default.
• W4385952914 creator A5044796160 @default.
• W4385952914 creator A5059219514 @default.
• W4385952914 creator A5074264694 @default.
• W4385952914 creator A5074866697 @default.
• W4385952914 creator A5083673194 @default.
• W4385952914 date "2023-08-17" @default.
• W4385952914 modified "2023-10-12" @default.
• W4385952914 title "Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma" @default.
• W4385952914 cites W2082708772 @default.
• W4385952914 cites W2107277218 @default.
• W4385952914 cites W2144728882 @default.
• W4385952914 cites W2192080449 @default.
• W4385952914 cites W2340862784 @default.
• W4385952914 cites W2592673843 @default.
• W4385952914 cites W2755114342 @default.
• W4385952914 cites W2790173378 @default.
• W4385952914 cites W2803679599 @default.
• W4385952914 cites W2807637103 @default.
• W4385952914 cites W2864786814 @default.
• W4385952914 cites W2886502012 @default.
• W4385952914 cites W2886837533 @default.
• W4385952914 cites W2889646458 @default.
• W4385952914 cites W2906581363 @default.
• W4385952914 cites W2917285914 @default.
• W4385952914 cites W2918633605 @default.
• W4385952914 cites W2921866483 @default.
• W4385952914 cites W2943335541 @default.
• W4385952914 cites W2955184254 @default.
• W4385952914 cites W2970351372 @default.
• W4385952914 cites W2973021197 @default.
• W4385952914 cites W2998859344 @default.
• W4385952914 cites W3004303031 @default.
• W4385952914 cites W3005470808 @default.
• W4385952914 cites W3014823961 @default.
• W4385952914 cites W3046812880 @default.
• W4385952914 cites W3164922049 @default.
• W4385952914 cites W3176532045 @default.
• W4385952914 cites W3206783250 @default.
• W4385952914 cites W4206826422 @default.
• W4385952914 cites W4220862006 @default.
• W4385952914 cites W4230177651 @default.
• W4385952914 cites W4366782957 @default.
• W4385952914 doi "https://doi.org/10.3892/etm.2023.12170" @default.
• W4385952914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37664681" @default.
• W4385952914 hasPublicationYear "2023" @default.
• W4385952914 type Work @default.
• W4385952914 citedByCount "0" @default.
• W4385952914 crossrefType "journal-article" @default.
• W4385952914 hasAuthorship W4385952914A5002802795 @default.
• W4385952914 hasAuthorship W4385952914A5044796160 @default.
• W4385952914 hasAuthorship W4385952914A5059219514 @default.
• W4385952914 hasAuthorship W4385952914A5074264694 @default.
• W4385952914 hasAuthorship W4385952914A5074866697 @default.
• W4385952914 hasAuthorship W4385952914A5083673194 @default.
• W4385952914 hasBestOaLocation W43859529141 @default.
• W4385952914 hasConcept C121608353 @default.
• W4385952914 hasConcept C126322002 @default.
• W4385952914 hasConcept C141071460 @default.
• W4385952914 hasConcept C142424586 @default.
• W4385952914 hasConcept C197934379 @default.
• W4385952914 hasConcept C2776364478 @default.
• W4385952914 hasConcept C2777701055 @default.
• W4385952914 hasConcept C2780850621 @default.
• W4385952914 hasConcept C3875195 @default.
• W4385952914 hasConcept C71924100 @default.
• W4385952914 hasConcept C86803240 @default.
• W4385952914 hasConcept C87355193 @default.
• W4385952914 hasConcept C90924648 @default.
• W4385952914 hasConceptScore W4385952914C121608353 @default.
• W4385952914 hasConceptScore W4385952914C126322002 @default.
• W4385952914 hasConceptScore W4385952914C141071460 @default.
• W4385952914 hasConceptScore W4385952914C142424586 @default.
• W4385952914 hasConceptScore W4385952914C197934379 @default.
• W4385952914 hasConceptScore W4385952914C2776364478 @default.
• W4385952914 hasConceptScore W4385952914C2777701055 @default.
• W4385952914 hasConceptScore W4385952914C2780850621 @default.
• W4385952914 hasConceptScore W4385952914C3875195 @default.
• W4385952914 hasConceptScore W4385952914C71924100 @default.
• W4385952914 hasConceptScore W4385952914C86803240 @default.
• W4385952914 hasConceptScore W4385952914C87355193 @default.
• W4385952914 hasConceptScore W4385952914C90924648 @default.
• W4385952914 hasIssue "4" @default.
• W4385952914 hasLocation W43859529141 @default.
• W4385952914 hasLocation W43859529142 @default.
• W4385952914 hasLocation W43859529143 @default.
• W4385952914 hasOpenAccess W4385952914 @default.
• W4385952914 hasPrimaryLocation W43859529141 @default.
• W4385952914 hasRelatedWork W2251648452 @default.
• W4385952914 hasRelatedWork W2916176185 @default.
• W4385952914 hasRelatedWork W2917403768 @default.
• W4385952914 hasRelatedWork W2936186479 @default.
• W4385952914 hasRelatedWork W2952260713 @default.
• W4385952914 hasRelatedWork W2969241243 @default.
• W4385952914 hasRelatedWork W3028773865 @default.
• W4385952914 hasRelatedWork W3142239825 @default.
• W4385952914 hasRelatedWork W4220818326 @default.
• W4385952914 hasRelatedWork W4381594543 @default.

• next